- Home
- GMAB vs UHS Comparison
GMAB vs UHS Comparison
Compare GMAB & UHS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GMAB
- UHS
- Stock Information
- Founded
- GMAB 1999
- UHS 1978
- Country
- GMAB Denmark
- UHS United States
- Employees
- GMAB N/A
- UHS N/A
- Industry
- GMAB Biotechnology: Pharmaceutical Preparations
- UHS Hospital/Nursing Management
- Sector
- GMAB Health Care
- UHS Health Care
- Exchange
- GMAB Nasdaq
- UHS Nasdaq
- Market Cap
- GMAB 13.7B
- UHS 12.1B
- IPO Year
- GMAB N/A
- UHS N/A
- Fundamental
- Price
- GMAB $21.88
- UHS $168.96
- Analyst Decision
- GMAB Buy
- UHS Buy
- Analyst Count
- GMAB 7
- UHS 17
- Target Price
- GMAB $37.80
- UHS $222.25
- AVG Volume (30 Days)
- GMAB 1.5M
- UHS 856.4K
- Earning Date
- GMAB 08-07-2025
- UHS 07-28-2025
- Dividend Yield
- GMAB N/A
- UHS 0.47%
- EPS Growth
- GMAB 276.80
- UHS 51.30
- EPS
- GMAB 18.36
- UHS 17.80
- Revenue
- GMAB $3,230,902,140.00
- UHS $16,084,073,000.00
- Revenue This Year
- GMAB $747.74
- UHS $9.34
- Revenue Next Year
- GMAB $14.81
- UHS $5.55
- P/E Ratio
- GMAB $1.19
- UHS $9.50
- Revenue Growth
- GMAB 25.43
- UHS 9.73
- 52 Week Low
- GMAB $17.24
- UHS $153.99
- 52 Week High
- GMAB $28.56
- UHS $243.25
- Technical
- Relative Strength Index (RSI)
- GMAB 56.89
- UHS 34.78
- Support Level
- GMAB $21.10
- UHS $168.61
- Resistance Level
- GMAB $21.90
- UHS $185.00
- Average True Range (ATR)
- GMAB 0.39
- UHS 5.07
- MACD
- GMAB 0.11
- UHS -1.28
- Stochastic Oscillator
- GMAB 79.95
- UHS 2.78
About GMAB Genmab A/S ADS
Genmab is a Copenhagen-based biotechnology company specializing in antibody therapeutics for the treatment of cancer. Genmab's proprietary antibody technologies are DuoBody, HexaBody, DuoHexaBody, and HexElect. Johnson & Johnson partnered with Genmab to create Darzalex, which is regarded as the standard of care for multiple myeloma and is Genmab's leading product. Genmab also has Tepezza for thyroid eye disease (partnered with Horizon), Kesimpta for relapsing multiple sclerosis (partnered with Novartis), Rybrevant (partnered with Johnson & Johnson) for non-small cell lung cancer (NSCLC), Tivdak (partnered with Seagen) for cervical cancer, and Epkinly (partnered with AbbVie) for diffuse large B-cell lymphoma. Genmab has several pipeline candidates targeting other oncologic indications.
About UHS Universal Health Services Inc.
Universal Health Services Inc owns and operates acute care hospitals, behavior health centers, surgical hospitals, ambulatory surgery centers, and radiation oncology centers. The firm operates in two segments: Acute Care Hospital Services and Behavioral Health Services. The company generates the majority of its revenue from the Acute Care Hospital Services segment. The Acute Care Hospital Services segment includes the firm's acute care hospitals, surgical hospitals, and surgery and oncology centers.